Overview of Avitene

What is Avitene? (Microfibrillar Collagen Hemostat)

Quick Facts

Property	Description
Active ingredient	Microfibrillar Collagen (Type I)
Form	Sterile Powder, Fibrillar, or Sponge
Pharmacological class	Topical Hemostatic Agent (Hemostat)
Common use	Adjunct to Surgical Hemostasis
Origin	Biologic Material (Bovine source)

What is Avitene and What Type of Medical Agent is It?

Avitene is recognized as a Microfibrillar Collagen Hemostat (MCH), a specialized absorbable medical device utilized by surgeons to control localized bleeding that may be difficult to manage with conventional techniques. Its classification as a medical device is a distinguishing feature, formally established under a generic class identified as an "Agent, absorbable hemostatic, collagen based." Functionally, it is categorized as a Topical Hemostatic Agent, serving as an essential aid to surgical hemostasis in contexts such as solid organ surgery or vascular grafting, where suture lines may exhibit persistent oozing.

Composition, Origin, and Physical Form of Avitene

The core active component is purified Microfibrillar Collagen, predominantly composed of Type I Collagen. It is prepared from processed bovine sources, designating it a biologic material. The fibrillar structure and highly purified composition are differentiating factors, distinguishing it from other agents that may incorporate gelatin or oxidized cellulose. Collagen-based hemostats offer a highly effective physical matrix for clot formation. Avitene is designed for Topical Application and is supplied in sterile forms, including a fine, fibrous powder or compressed fibrillar sponge, maximizing the material’s surface area for immediate contact with blood.

The Core Purpose of Avitene: Achieving Hemostasis

The fundamental purpose of Avitene is to rapidly promote the arrest of bleeding by initiating the natural clotting process. The collagen acts as a physical scaffold that immediately attracts and supports platelet aggregation when applied to the bleeding site. MCH products are effective at controlling capillary and venous oozing. This material is primarily reserved for use by operating room personnel as a supplementary tool in controlling persistent non-arterial bleeding. A key advantage is that the material is fully absorbable by the body, ensuring safe integration and degradation over time once successful hemostasis is achieved.

What side effects are possible with Avitene?

Possible side effects and safety information

Regulatory documentation for Avitene (Microfibrillar Collagen Hemostat), which is classified as a medical device derived from a bovine source, documents a safety profile centered on localized complications and immune responses rather than systemic pharmacological effects.

Adverse reactions are reported as Adverse Experiences and Complications rather than being categorized by standard frequency bands (e.g., Common, Rare).

Documented Adverse Reactions and Safety Concerns

System-Organ Class	Key Adverse Reactions Listed in Labeling
Immune System	Allergic reaction, hypersensitivity (due to bovine collagen).
Surgical Complications	Infection, abscess formation, hematoma, adhesion formation.
General/Application Site	Local tissue reaction, seroma, foreign body reaction.
Nervous System	Pain, numbness, or paralysis (when left in bony enclosures or near neural spaces).

Serious adverse reactions documented in regulatory sources include severe hypersensitivity or anaphylaxis related to the bovine material, as well as serious infection/abscess formation and potential neural deficits following incorrect use in confined spaces.

Safety Restrictions and Limitations

The product label includes mandatory restrictions for use. Avitene is contraindicated in patients with a known sensitivity to bovine collagen materials. It is also restricted from use in closing skin incisions, where it may interfere with the healing process. Furthermore, regulatory guidelines advise against using the material in the presence of frank infection or packing it tightly into cavities, especially those near the central nervous system.

The official safety information structures the risk profile around the local environment of its application and its biologic origin. This approach focuses on mitigating site-specific and material-related risks, which are distinct from the systemic side effects of absorbed pharmacological agents.

Overdose and Emergency Response

Avitene Overdose and when to seek help

Avitene (Microfibrillar Collagen Hemostat or MCH) is a medical device, not a systematically absorbed drug. Therefore, its safety profile defines "overdose" risk as the consequence of physical misapplication (using excessive material or improper placement), rather than pharmacological toxicity.

Documented Overdose-Related Risks

Official regulatory documents describe the complications of failing to remove excess material or using it improperly, particularly in confined spaces:

Mass and Lesion Formation: Failure to remove excess material may result in a recurring mass, a space-occupying lesion, or a foreign body reaction.
Compression and Functional Deficits: Packing the material too tightly, especially in bony enclosures such as those near the Central Nervous System, may cause compression necrosis and interfere with normal function, potentially leading to paralysis or other neural deficits.

Required Emergency Actions

The primary instruction provided in the official labeling to prevent these complications is the mandatory removal of excess material after hemostasis is achieved.

Urgent medical attention is required if signs of infection or abscess develop at the application site, as surgical re-operation may be necessary for drainage and management of the complication.

Therapeutic Uses of Avitene

What Avitene Treats: Main Uses and Benefits

The utility of Avitene (Microfibrillar Collagen Hemostat) is to provide essential support for blood control in surgical settings where standard methods may be insufficient. This specialized agent supports the arrest of bleeding across various procedures.

This product is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

It is applied across domains where additional symptomatic support is needed, primarily to manage persistent capillary and venous oozing, surface bleeding in vascular organs like the liver and spleen, and hemorrhage from cancellous bone.

“Avitene provides a supportive method to achieve hemostasis in conditions where groups of symptoms related to localized bleeding become more disruptive.”

This material is also considered relevant for patients whose bodies face an elevated risk of hemorrhage due to underlying conditions, such as certain coagulopathies or liver disease, offering a therapeutic benefit that may help patients cope more steadily with symptom fluctuations during the procedure.

Quick Fact: Relief for Persistent Oozing

Avitene is primarily used to address the symptom pattern of diffuse, localized hemorrhage that cannot be stopped by mechanical means, which generally contributes to minimizing the patient's overall blood loss during the procedure.

Regulatory References

indicated for use in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical

Eligibility and Restrictions for Use

Eligibility Scope

Category	Official Regulatory Classification
Populations for whom use is allowed:	Established for use as an adjunct to hemostasis in surgical procedures on the general adult surgical population where conventional bleeding control methods are impractical or ineffective.
Populations for whom use is contraindicated:	Patients with known sensitivity or allergy to bovine collagen. Patients requiring the device for the closure of skin incisions. Procedures involving the attachment of prosthetic materials using methylmethacrylate adhesives on bone surfaces.
Age-related eligibility rules:	Safety and effectiveness have not been clinically evaluated or established in the pediatric population (children and infants).
Pregnancy and lactation eligibility status:	Pregnancy: Use is documented as acceptable only when clearly needed, as well-controlled studies in pregnant women are not available. Lactation: Official labeling does not explicitly describe restrictions or recommendations.

Eligibility-Related Restrictions

Official labeling strictly prohibits certain applications and patient conditions:

Intravascular or Systemic Use: Avitene is not for injection, intraocular, or intravascular use, as systemic entry poses risks.
Bleeding Type: The product should not be used in instances of pumping arterial hemorrhage.
Contaminated Areas: Use requires caution in the presence of infection or in contaminated areas, as foreign substances may enhance infection.
Closed Cavities: The material should not be packed tightly in rigid cavities, such as within the CNS, where potential material expansion could interfere with normal function.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Avitene by establishing absolute non-eligibility based on hypersensitivity to the bovine-derived component and prohibiting all non-topical routes of administration. The profile restricts use to specific localized bleeding contexts, thereby excluding populations where safety data is insufficient, such as in the pediatric age group.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products for Avitene

Avitene (Microfibrillar Collagen Hemostat or MCH) is a topical hemostatic agent and is not systemically absorbed. Consequently, regulatory documents state that there are no known drug interactions with orally or parenterally administered medications.

Interactions are strictly limited to local effects with other products and materials used in the operative field. These constraints are necessary to maintain the hemostatic function of Avitene or prevent structural complications.

Procedural and Local Product Interactions

Interaction Classification	Official Constraint
Contraindicated Combinations	Must not be used on bone surfaces where prosthetic materials will be attached using methylmethacrylate adhesives, as this can reduce the adhesive bond strength. Also, avoid use in the closure of skin incisions.
Efficacy-Impairing Agents	Moistening the product or wetting it with saline or thrombin officially impairs its hemostatic efficacy. The product must be applied in a dry state.
Autologous Blood Salvage	Avoid use in conjunction with autologous blood salvage circuits, as product fragments may pass through filtration systems.

Systemic Interactions: No known interactions are documented with food, alcohol, or systemic herbal products.

Mechanism of Action

Avitene (Microfibrillar Collagen Hemostat) exerts its effect through a localized, synergistic physical and biological mechanism that targets the process of hemostasis (blood clotting). It provides a stimulus that engages the intrinsic coagulation pathway locally, initiating the formation of a plug at the application site.

Physical Scaffolding and Platelet Adhesion

This mechanism begins with the material's fine, fibrous structure providing a physical scaffold that is highly attractive to circulating platelets. Upon contact, the collagen acts as an agonist for platelet surface receptors, instantly triggering adhesion (sticking) and aggregation (clumping). This localized recruitment creates a dense, concentrated surface of activated platelets, a process that initiates the formation of a localized plug.

Cascade Acceleration and Fibrin Formation

The aggregated and activated platelets release critical clotting factors, including phospholipids and thrombin activators, which significantly increase the rate of the intrinsic coagulation cascade within the localized area. Simultaneously, the collagen itself activates factor XII to further promote clotting. This combined biological activity contributes to the enhanced formation of fibrin strands which, along with the physical collagen structure and platelet plug, produces a localized, physical barrier that contributes to hemostasis.

Dosage and Administration Information

How Avitene is Used

Avitene (Microfibrillar Collagen Hemostat) is a surgical device utilized solely for topical application directly onto a localized bleeding site, and is explicitly not approved for injection into the bloodstream, intraocular, or intravascular spaces. Its use is limited to operating room personnel as an adjunct to hemostasis.

Application Principles and Dosing

The usage of Avitene is procedural, requiring the application of the minimal amount necessary to achieve hemostasis, without adherence to a fixed dose. For instance, one gram of the powder form is generally sufficient for approximately a 50 cm^2 area when managing capillary bleeding. It is supplied as a dry powder or non-woven sheet, and is designated for single use only.

Administration Conditions and Technique

The product must be applied dry to the bleeding surface, which must be clean and free of excessive fluid prior to application. The material is not moistened with saline or thrombin beforehand, as this practice impairs its intended action.

After the material is placed, manual pressure is applied for a duration that must be maintained until hemostasis is achieved. This pressure duration is variable, ranging from approximately one minute for minor oozing up to three to five minutes for more substantial bleeding, as determined by the surgical context. Following successful blood control, excess material should be removed from the site, as failure to do so may interfere with normal function, and the material is not tightly packed into confined bony cavities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Avitene

This section provides a summary of the available research and clinical studies on Avitene (microfibrillar collagen hemostat). It focuses on what types of studies were conducted and what was measured, aiming to reflect the evidence landscape transparently without offering clinical recommendations or individual advice. Research describes group patterns, not personal outcomes.

Research Evidence for Use as Adjunct to Hemostasis in Surgical Procedures

Avitene was studied for its use as an aid in controlling bleeding during various surgical operations, especially when conventional methods, such as sutures or cautery, were not fully controlling the bleeding. Research includes systematic reviews, controlled clinical evaluations where Avitene was compared to other products, such as gelatin sponge or oxidized cellulose, and case series describing clinical experiences.

Researchers primarily studied adult patients undergoing a broad range of surgical procedures, including hepatic, orthopedic, splenic, and neurosurgery. The main outcomes monitored in these studies were the time required to achieve hemostasis (when bleeding cessation occurred), measurements of blood loss volume, and documentation of the need for blood transfusions.

Long-Term Studies and Follow-up After Avitene Use

Research primarily focuses on short-term symptom changes that occur during the operation and immediately afterward. Follow-up durations were limited in many studies, meaning that the monitoring of patients often did not extend for a long time after the surgery. Long-term effects are not fully established.

Evidence in Special Patient Populations

Research explored the use of Avitene in adult patients, including some with pre-existing conditions that affect blood clotting. However, data for certain groups remain insufficient. For example, there is limited information available from studies focused specifically on the use of Avitene in pediatric (children) or geriatric (older adult) populations. The results apply only to the populations studied.

What is Still Uncertain About Avitene Research

A critical point is that long-term outcomes are not well characterized. Research provides insight into short-term changes, but there is limited information for long-term outcomes concerning the stability of the surgical site and the tracking of the material absorption over extended time periods. There is also a lack of recent, large-scale Randomized Controlled Trials (RCTs) to compare Avitene against other available hemostatic products under highly standardized conditions.

Frequently Asked Questions (FAQ)

Common questions about Avitene (FAQ)

Q: What is the difference between the 'Flour' and 'Sheet' forms of Avitene?

A: Avitene is manufactured in different forms to suit various needs during surgery. The 'Flour' form is a fine, loose powder designed to easily conform and adhere to irregular spaces or surfaces that are hard to reach. The 'Sheet' form is a non-woven material that can be cut to size, making it ideal for flat surfaces or for wrapping around blood vessels.

Q: Is Avitene an absorbable material?

A: Yes, Avitene is formally classified as an absorbable collagen hemostat. The material, which is purified bovine collagen, is designed to be fully broken down and naturally absorbed by the body over a period of time after it has successfully helped stop the bleeding (hemostasis).

Q: How quickly does the body absorb or break down Avitene?

A: Studies referenced in official regulatory documentation describe the material’s absorption rate. When Avitene is left in the body, evidence indicates that it is typically absorbed in less than 90 days. The exact speed can depend on the amount used and the surgical site.

Q: Is Avitene ever removed after a surgical procedure?

A: The material intended to form the hemostatic clot is absorbable and may be left in the body. However, official instructions indicate that any excess material not involved in the clot should be removed by the surgeon after the bleeding has stopped.

Q: Can Avitene be used in a dental procedure, like a tooth extraction?

A: Official information indicates that Avitene is designed for use across a wide range of surgical specialties, including oral and dental surgical applications. Adverse experience reports have mentioned an increased incidence of alveolalgia (dry socket) when the product was used for packing after dental extraction.

Q: Is it common to have an allergic reaction to a bovine-derived product like Avitene?

A: Hypersensitivity and allergic reactions related to the bovine collagen material are listed as a documented adverse reaction in the safety profile. The official information does not use terms like 'common' or 'rare' to describe the exact frequency. Because of this risk, the product is contraindicated (should not be used) in any patient with a known sensitivity to bovine collagen.

Q: What is the risk of a foreign body reaction from Avitene?

A: A foreign body reaction, which is a localized tissue response to the presence of the collagen material, is listed as a reported adverse reaction. Official precautions advise that any excess material left in the body has been associated with this type of reaction. Case reports have described that this reaction may sometimes present as a recurring mass or lesion upon imaging years after the surgery.

Q: Can Avitene be used on patients who have an active infection?

A: Official warnings state that caution should be used in the presence of contamination or infection. As with any foreign substance, the use of Avitene in contaminated wounds may enhance infection. The safety information notes that its use requires caution in the presence of contamination or infection.

Q: What is the concern about using Avitene near the spine or large nerves?

A: The official product guidance advises surgeons against tightly packing the material in confined bony cavities near the central nervous system. The physical presence of the material in non-yielding spaces has been associated with potential adverse reactions, such as pain, numbness, or paralysis, by potentially interfering with nerve function.

Q: Is it possible for Avitene fragments to be filtered out during a blood salvage procedure?

A: Official documentation includes a constraint to avoid using Avitene alongside autologous blood salvage circuits. This is a technical precaution due to the fact that fragments of the product may pass through the filtration systems used in the equipment.

Q: Is there research evidence showing Avitene is effective in complex surgeries?

A: Research has examined the use of Avitene as an aid to hemostasis in a broad range of surgical procedures, including complex procedures like neurosurgery. The available evidence, based on studies where outcomes were monitored, reports that the product has shown positive observations or findings in these applications where stopping local bleeding is critical to surgical success.

Q: What kind of studies are available on the long-term effects of using Avitene?

A: Research primarily focuses on short-term outcomes observed during and immediately after the operation. Long-term follow-up and the complete tracking of the material’s absorption over extended time periods are not fully established. The material is described in regulatory documents as an absorbable device.

Q: Are there any known issues with using Avitene in pediatric patients (children)?

A: Official labeling states that the safety and effectiveness have not been clinically evaluated or established in the pediatric population (children and infants). Because safety and effectiveness have not been established in this age group, the conditions of use are based on data from adult surgical populations.

Q: What happens if Avitene is left on a non-bleeding surface?

A: The product is designed to function as an adjunct to hemostasis when applied to a bleeding surface. Official instructions mandate that the product should be used on a bleeding surface that is clean and dry (free of excessive fluid) to ensure its hemostatic efficacy is not impaired.

Q: Is there a risk of Avitene causing swelling or tissue compression?

A: While some information suggests the material itself does not significantly swell after implantation, official warnings still advise against tight packing in confined areas due to the potential for interference with function. Regulatory documents have also reported seroma (a fluid collection that can create a mass effect) as an adverse reaction.

Q: Does the use of Avitene interfere with the natural wound healing process?

A: Avitene is strictly contraindicated for the closure of skin incisions. Official documentation clarifies that this restriction is due to the simple mechanical interposition of the dry collagen. This physical presence may interfere with the proper healing or re-approximation of the skin edges.

Q: Why are there warnings against reprocessing or reusing Avitene?

A: Official warnings strictly prohibit reusing or reprocessing Avitene. The primary reasons are that these actions may compromise the structural integrity and critical performance characteristics of the device, which poses a potential risk to the patient. Additionally, it creates a risk of contamination or cross-infection.

How should Avitene be stored and disposed of?

Storage and Disposal Requirements for Avitene™

Avitene™ (Microfibrillar Collagen Hemostat) is a sterile, single-use medical device, and storage protocols are designed to maintain its sterility. Specific temperature requirements are not universally stated in the labeling, but the product must be kept in its original sterile packaging until use to prevent contamination.

Handling and Disposal Rules

The device must not be reused, reprocessed, resterilized, or repackaged under any circumstances. Official instructions prohibit re-sterilization methods like autoclaving, which inactivates the product, and ethylene oxide, which causes a chemical reaction. Avitene is for single use only; any portion of the product that is opened but unused must be discarded according to institutional and local regulations.

Avitene